Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 16;6(8):e1338236. doi: 10.1080/2162402X.2017.1338236

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 5. — The abscopal effect of LTX-315 in a 3-tumor model. (A) Tumor cells (2·10⁵ rTMSCs) were inoculated on day ÷2 s.c. in the right flank (primary treated lesion), day 0 (1·10⁴ rTMSCs) s.c. in the contralateral flank (secondary non-treated lesion) and (1·10⁴ rTMSCs) i.p. (tertiary non-treated lesion) into PVG rats (n = 12). The primary lesion was treated with 1 mg of LTX-315 i.t. daily for 7 d. Control rats (n = 3) for each tumor site were included. Representative whole-body bioluminescence images of LTX-315 treated and untreated rats; (B) primary lesion, (D) secondary lesion and (F) peritoneal tumor are presented. The mean ± SD of tumor burden is plotted (treated; bold line, untreated; dashed line) for the primary (C), the secondary (E) and the third (G) tumor. Results are presented as a mean ± SD.